Eli Lilly reported second-quarter 2026 results on August 5 that beat analyst expectations and raised its full-year guidance, while confirming that its Biologics License Application (BLA) for retatrutide remains on track for a first-quarter 2027 submission to the U.S. Food and Drug Administration.
The earnings report — the first to include sales of Lilly’s newly approved oral obesity pill Foundayo — reinforces the financial engine behind retatrutide’s development. For Canadians following the drug’s path toward Health Canada, the update confirms the timeline laid out in our earlier coverage of the Q1 2027 filing, now backed by the company’s statement that the clinical data package for retatrutide is complete.
The numbers
- Revenue rose 48% year over year to $23.0 billion in Q2 2026, driven primarily by Mounjaro and Zepbound volume (Lilly press release).
- Reported EPS was $7.94 (up 26%); non-GAAP EPS was $8.38 (up 33%). Both figures included $3.03 per share of acquired in-process R&D charges tied to Lilly’s acquisition spree.
- Full-year 2026 guidance raised: revenue of $85.0–87.0 billion (up from $82–85 billion) and non-GAAP EPS of $35.50–36.50 (CNBC).
- Mounjaro grew 91% to $9.94 billion in the quarter; Zepbound grew 46% to $4.93 billion; Foundayo, the oral GLP-1 pill approved in April, contributed $98 million in its first quarter.
- Lilly held 60.9% of the U.S. obesity and diabetes drug market in Q2, versus 38.8% for Novo Nordisk, according to the company’s earnings presentation.
Retatrutide: “clinical data package now complete”
The most consequential line for retatrutide watchers came in the pipeline section of the press release: Lilly said it had generated positive data from three additional Phase 3 trials of retatrutide in obesity, and that the “clinical data package is now complete to support global registrations for obesity, obstructive sleep apnea, and knee osteoarthritis pain, with plans to submit a Biologics License Application to the U.S. FDA in the first quarter of 2027.”
That statement does two things: it formally locks in the Q1 2027 filing window that had been reported since late July, and it signals that the company considers its five positive Phase 3 readouts — TRIUMPH-1, TRIUMPH-2, two additional obesity trials, and TRIUMPH-4 — sufficient to support registration across three indications without waiting for further data.
CEO David Ricks tied the pipeline to the balance sheet: “With our next-generation weight-loss medicine retatrutide and its complete clinical data package in hand, new manufacturing capacity coming online, and exciting new assets entering our pipeline through business development, Lilly’s future, after 150 years, has never been brighter.” The company also committed an additional $4.5 billion to expand its Indiana manufacturing sites.
Analyst reaction
Following the earnings report, several banks raised their price targets on Lilly stock, according to NAI500: Morgan Stanley to $1,419, BMO Capital to $1,400, and Wells Fargo to $1,330, against a consensus target of $1,276.96. The article notes a more aggressive bull case of $1,750 by 2027 — a scenario that depends on retatrutide’s regulatory journey proceeding without safety surprises.
Canadian context
For Canadians, the key implications are unchanged but now rest on firmer ground:
- Health Canada timing: With the U.S. BLA confirmed for Q1 2027, a parallel Health Canada submission would put a potential Canadian approval in late 2027 or early 2028, consistent with earlier analysis on this site.
- Supply and manufacturing: The $4.5 billion Indiana expansion and Lilly’s broader manufacturing build-out are what will ultimately determine Canadian supply volumes once the drug is approved. Lilly markets tirzepatide under the Zepbound name in Canada, Japan, and the United States, a brand infrastructure that would likely extend to retatrutide.
- Canadian investors: The earnings beat and raised guidance extend a run of positive financial catalysts for the obesity market. NAI500, a Vancouver-based financial media outlet, is among the outlets framing retatrutide as the next growth driver for the stock.
- What to watch: The next major catalyst is TRIUMPH-OUTCOMES, the cardiovascular outcomes trial that could support a cardioprotective label claim. A readout is expected in late 2026 or early 2027.
As always, retatrutide remains an investigational drug not approved by Health Canada or the FDA. Canadians should only obtain it through legitimate clinical trials or Health Canada’s Special Access Programme, and should avoid unregulated products sold online.
Sources
- Eli Lilly and Company: “Lilly reports second-quarter 2026 financial results, raises full-year guidance, and highlights continued growth and pipeline progress” — August 5, 2026
- CNBC: “Eli Lilly easily tops quarterly estimates, raises outlook as Zepbound and Mounjaro sales surge” — August 5, 2026
- NAI500: “Eli Lilly Locks In Retatrutide FDA Filing Date — Can the Stock Climb to $1,750 by 2027?” — August 7, 2026
- CNBC: “Eli Lilly will file for approval of retatrutide obesity drug in 2027” — July 23, 2026
- Reuters: “Lilly announces more next-gen obesity drug data, plans Q1 2027 FDA application” — July 23, 2026